Is MYALGIA a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed MYALGIA.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 18 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported MYALGIA to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and MYALGIA. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause MYALGIA, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes MYALGIA. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if MYALGIA ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing MYALGIA: 18
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where MYALGIA is a reported side effect: 0.5407%

FDA reports of any drug causing MYALGIA : 49594
Average percentage for all medicated patients where MYALGIA is reported as a complication: 0.3108%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with MYALGIA:

LIPITOR (6687 patients)
ASPIRIN (4311 patients)
CRESTOR (4284 patients)
FOSAMAX (3629 patients)
ZOCOR (2441 patients)
SIMVASTATIN (2294 patients)
SYNTHROID (1805 patients)
ATENOLOL (1626 patients)
FORTEO (1607 patients)
LISINOPRIL (1563 patients)
ACCUTANE (1557 patients)
VIOXX (1554 patients)
ZETIA (1541 patients)
LYRICA (1457 patients)
PREDNISONE (1436 patients)
HUMIRA (1416 patients)
NEXIUM (1415 patients)
PLAVIX (1273 patients)
REMICADE (1263 patients)
ZOMETA (1254 patients)
OMEPRAZOLE (1204 patients)
LEVAQUIN (1189 patients)
NIASPAN (1180 patients)
LASIX (1121 patients)
HYDROCHLOROTHIAZIDE (1069 patients)
VITAMIN D (1063 patients)
NEURONTIN (1028 patients)
RECLAST (996 patients)
ENBREL (977 patients)
XANAX (967 patients)
LEVOTHYROXINE SODIUM (958 patients)
NORVASC (951 patients)
BONIVA (950 patients)
CALCIUM (932 patients)
FOLIC ACID (927 patients)
AVONEX (925 patients)
PRILOSEC (914 patients)
FUROSEMIDE (898 patients)
TOPROL-XL (873 patients)
CELEBREX (853 patients)
ACETAMINOPHEN (848 patients)
METHOTREXATE (834 patients)
COUMADIN (824 patients)
ZOLOFT (817 patients)
SEROQUEL (805 patients)
IBUPROFEN (795 patients)
AMBIEN (775 patients)
DIOVAN (750 patients)
ALBUTEROL (741 patients)
PREVACID (739 patients)
METFORMIN HCL (714 patients)
VYTORIN (710 patients)
CYMBALTA (680 patients)
CHANTIX (656 patients)
TYSABRI (650 patients)
PROTONIX (645 patients)
VICODIN (644 patients)
AMLODIPINE (642 patients)
PAXIL (639 patients)
FISH OIL (637 patients)
ALLOPURINOL (636 patients)
SINGULAIR (633 patients)
LEXAPRO (613 patients)
AREDIA (604 patients)
GABAPENTIN (599 patients)
ACTONEL (599 patients)
PERCOCET (579 patients)
ATORVASTATIN CALCIUM (568 patients)
GLEEVEC (565 patients)
ADVAIR DISKUS 100/50 (564 patients)
LORAZEPAM (561 patients)
METOPROLOL TARTRATE (558 patients)
ATIVAN (553 patients)
PREDNISONE TAB (548 patients)
PREMARIN (542 patients)
OXYCONTIN (540 patients)
POTASSIUM CHLORIDE (533 patients)
MULTI-VITAMINS (529 patients)
PRAVACHOL (527 patients)
TRICOR (523 patients)
PREDNISOLONE (514 patients)
PEGASYS (512 patients)
MULTI-VITAMIN (510 patients)
CLONAZEPAM (507 patients)
ALLEGRA (506 patients)
ZYRTEC (492 patients)
RAMIPRIL (490 patients)
LANTUS (490 patients)
MAGNEVIST (485 patients)
PROZAC (480 patients)
DIAZEPAM (478 patients)
COZAAR (475 patients)
METOPROLOL (473 patients)
EFFEXOR (470 patients)
SIMCOR (470 patients)
VITAMIN E (469 patients)
DEXAMETHASONE (467 patients)
REBIF (461 patients)
TRAMADOL HCL (455 patients)
INSULIN (454 patients)
PRAVASTATIN (449 patients)
ALENDRONATE SODIUM (445 patients)
ALPRAZOLAM (443 patients)
DIGOXIN (435 patients)
WARFARIN SODIUM (425 patients)
WELLBUTRIN (422 patients)
KLONOPIN (419 patients)
ASCORBIC ACID (418 patients)
CIPROFLOXACIN (415 patients)
DURAGESIC-100 (413 patients)
FLEXERIL (413 patients)
ARIMIDEX (411 patients)
SPIRIVA (404 patients)
LEVOXYL (402 patients)
LAMICTAL (399 patients)
ALTACE (394 patients)
GLUCOPHAGE (393 patients)
ACTOS (388 patients)
OXYCODONE HCL (388 patients)
ZANTAC (386 patients)
ACETYLSALICYLIC ACID (384 patients)
METFORMIN (382 patients)
ACETYLSALICYLIC ACID SRT (378 patients)
COREG (378 patients)
TYLENOL (374 patients)
AMOXICILLIN (367 patients)
SANDOSTATIN LAR (367 patients)
AVELOX (363 patients)
RIBAVIRIN (363 patients)
LANSOPRAZOLE (351 patients)
NITROGLYCERIN (351 patients)
CALCIUM CARBONATE (350 patients)
TRAZODONE HCL (343 patients)
XOLAIR (338 patients)
VALIUM (337 patients)
VITAMIN B-12 (337 patients)
ELAVIL (336 patients)
RANITIDINE (331 patients)
ACLASTA (330 patients)
CELEXA (328 patients)
FEMARA (326 patients)
FLONASE (326 patients)
EXJADE (324 patients)
CIPRO (323 patients)
BENADRYL (320 patients)
BYETTA (319 patients)
ZOFRAN (317 patients)
PROLIA (313 patients)
COPEGUS (312 patients)
CYCLOSPORINE (308 patients)
ZITHROMAX (307 patients)
DECADRON (307 patients)
HEPARIN SODIUM INJECTION (307 patients)
FOSAMAX PLUS D (304 patients)
REVLIMID (303 patients)
EFFEXOR XR (303 patients)
PEG-INTRON (301 patients)
BACTRIM (299 patients)
TYLENOL (CAPLET) (297 patients)
MORPHINE (291 patients)
CIALIS (288 patients)
NAPROXEN (287 patients)
TRILIPIX (287 patients)
ACYCLOVIR (285 patients)
CYCLOPHOSPHAMIDE (284 patients)
LOVASTATIN (281 patients)
LORTAB (281 patients)
CLARITIN (280 patients)
GLIPIZIDE (277 patients)
TAXOTERE (275 patients)
AMLODIPINE BESYLATE (274 patients)
SPIRONOLACTONE (272 patients)
PEPCID (272 patients)
VALTREX (271 patients)
VITAMINS (270 patients)
LOVAZA (268 patients)
EPOGEN (268 patients)
ATORVASTATIN (268 patients)
PROMETHAZINE (267 patients)
ACIPHEX (265 patients)
JANUVIA (264 patients)
CLARITHROMYCIN (263 patients)
VITAMINS (UNSPECIFIED) (260 patients)
FENOFIBRATE (259 patients)
GLYBURIDE (259 patients)
CITALOPRAM HYDROBROMIDE (259 patients)
VERAPAMIL (259 patients)
GEMFIBROZIL (255 patients)
BACLOFEN (254 patients)
[THERAPY UNSPECIFIED] (252 patients)
CARVEDILOL (252 patients)
TOPAMAX (252 patients)
FLOMAX (249 patients)
HYDROCODONE BITARTRATE (249 patients)
TAMOXIFEN CITRATE (247 patients)
BENICAR (247 patients)
AMITRIPTYLINE HCL (246 patients)
BETASERON (245 patients)
HUMALOG (245 patients)
CLONIDINE (245 patients)
SOLIRIS (244 patients)
AVANDIA (243 patients)
GLUCOSAMINE (241 patients)
MICARDIS (241 patients)
TEGRETOL (240 patients)
METOPROLOL SUCCINATE (240 patients)
COLACE (239 patients)
CLINDAMYCIN (238 patients)
TASIGNA (236 patients)
ULTRAM (235 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about MYALGIA and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.